Discovery and Antiviral Profile of New Sulfamoylbenzamide Derivatives as HBV Capsid Assembly Modulators.
暂无分享,去创建一个
A. Prandi | R. De Francesco | V. Summa | M. Iannacone | L. Guidotti | E. Monteagudo | R. Di Fabio | R. Sinisi | A. Patsilinakos | Luca Ferrante | P. Di Lucia | Elisa B. Bono | Leonardo Giustini | L. Donnici | Matteo Conti | M. de Matteo | Leda Ivanova Bencheva | P. Randazzo | Maria Vittoria Orsale
[1] M. Nassal,et al. The Hepatitis B Virus Nucleocapsid—Dynamic Compartment for Infectious Virus Production and New Antiviral Target , 2021, Biomedicines.
[2] M. Iannacone,et al. Immunobiology and pathogenesis of hepatitis B virus infection , 2021, Nature Reviews Immunology.
[3] Yuchen Xia,et al. Hepatitis B Virus cccDNA: Formation, Regulation and Therapeutic Potential. , 2020, Antiviral research.
[4] J. Neefs,et al. Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A-H clinical isolates and core site-directed mutants in vitro. , 2020, The Journal of antimicrobial chemotherapy.
[5] W. Kim,et al. Development of Hepatocellular Carcinoma in Patients With Suppressed Viral Replication: Changes in Risk Over Time , 2020, Clinical liver disease.
[6] A. Zlotnick,et al. Local stabilization of subunit-subunit contacts causes global destabilization of Hepatitis B virus capsids , 2020, bioRxiv.
[7] F. Zoulim,et al. Therapeutic strategies for hepatitis B virus infection: towards a cure , 2019, Nature Reviews Drug Discovery.
[8] Joan M. Block,et al. A global scientific strategy to cure hepatitis B. , 2019, The lancet. Gastroenterology & hepatology.
[9] D. Liotta,et al. Recent advances in the development of HBV capsid assembly modulators. , 2019, Current opinion in chemical biology.
[10] D. Hoffmann,et al. Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives. , 2019, ACS infectious diseases.
[11] G. Wong,et al. Unmet need in chronic hepatitis B management , 2019, Clinical and molecular hepatology.
[12] S. Kuduk,et al. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus , 2018, Antimicrobial Agents and Chemotherapy.
[13] T. Volz,et al. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection. , 2017, Gastroenterology.
[14] S. Yan,et al. Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection. , 2017, Journal of medicinal chemistry.
[15] F. García-Alcalde,et al. Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular Mechanisms , 2017, Scientific Reports.
[16] V. Wong,et al. Infection and Cancer: The Case of Hepatitis B. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Rodrigo Quiroga,et al. Vinardo: A Scoring Function Based on Autodock Vina Improves Scoring, Docking, and Virtual Screening , 2016, PloS one.
[18] C. Lukacs,et al. High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein , 2015, Proceedings of the National Academy of Sciences.
[19] Jiaqian Pan,et al. Anti-HBV Drugs: Progress, Unmet Needs, and New Hope , 2015, Viruses.
[20] David Ryan Koes,et al. Lessons Learned in Empirical Scoring with smina from the CSAR 2011 Benchmarking Exercise , 2013, J. Chem. Inf. Model..
[21] F. Chisari,et al. High-level hepatitis B virus replication in transgenic mice , 1995, Journal of virology.